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Introduction
Postural Orthostatic Tachycardia Syndrome, POTS, affects 1-3 million Americans and is
most common in young women younger than 35. POTS has a female to male ratio of 5:1. The
syndrome is not inherited, but the factors contributing to POTS development can be inherited
(GARD 2017). POTS is an autonomic dysfunction syndrome, where the autonomic nervous
system does not work correctly. The nervous system usually regulates blood vessel dilation and
heart rate to compensate for blood flow changes when going from sitting to standing. With
POTS, the heart cannot compensate for the blood flow dysregulation, and blood flow to the heart
and brain are compromised, resulting in characteristic symptoms of dizziness and fainting (NHS
2019). There is incomplete knowledge as to the pathophysiology of POTS. POTS has different
subtypes for the causative agent of postural tachycardia, and each subtype has multiple possible
factors that all ultimately cause the same symptoms (Wells et al. 2018). The multifactorial
possibilities include autonomic dysfunction, increased sympathetic tone, severe deconditioning,
autoimmunity, mast cell activation, and post-viral infection (Wells et al. 2018).
POTS’ pathophysiology considers the multiple possible subtypes: Neuropathic,
hyperadrenergic, volume dysregulation, deconditioning, hypovolemic, norepinephrine
transporter deficiency, and mast cell activation. There are unique barriers to diagnosing POTS
that include inconclusive testing and assumed mental illness in patients who complain of heart
symptoms that mimic anxiety. Lastly, the treatment of POTS incorporates pharmacological and
nonpharmacological treatments to reduce orthostatic tolerance and increase plasma blood
volume.
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Pathophysiology
Symptomology
Postural orthostatic tachycardia syndrome presents in individuals with a few distinct
symptoms and many non-specific symptoms to POTS. The main complaints seen in clinical
settings include cardiac symptoms and noncardiac symptoms. The cardiac symptoms seen most
often include rapid palpitation, lightheadedness, dyspnea (difficulty breathing), and chest
discomfort. The noncardiac symptoms most often seen include headaches, nausea,
tremulousness, sleep difficulties, mental clouding (brain fog), exercise intolerance, and chronic
fatigue (Halstead 2018). Noncardiac symptoms specific to the GI include chronic nausea,
vomiting, bloating, diarrhea, or severe constipation (Mehr et al. 2018). Symptoms cause
difficulties in completing daily activities like bathing oneself, performing housework, attending
school or one’s vocation, and performing said activities results in fatigue and an exacerbation of
symptoms (Halstead 2018).
POTS’ most characteristic symptoms are pre syncope, orthostatic intolerance,
tachycardia, difficulty concentrating, and lightheadedness. Many other symptoms present in
POTS patients, but it is often unclear and not correctly investigated whether the symptoms are
from comorbid factors or are distinctly from POTS. Unclear comorbidities create a diagnostic
dilemma because symptoms like sleep issues, headaches, diarrhea, and bloating are only
assumed to be caused by the POTS when these signs are seen in the general population separate
from POTS. It’s hypothesized that the ill-defined symptoms have caused an increase in POTS
diagnosis resulting in a lack of diagnostic focus. The major problem is that there is no set
2

POTS symptoms that are universally accepted, and POTS itself is not a disease but a syndrome
and often overlaps with other conditions (Olshansky et al. 2020). The symptoms shown in
Table 1 (Fedorowski 2019, p. 354) give a broad overview of patients’ most popular complaints
in a clinical setting and is sorted by the body system they affect. Cardiovascular symptoms are
characterized as main symptoms, while the noncardiovascular symptoms are accompanying
symptoms.
Patients’ cognitive impairment is often hard to explain in clinical and has come to be
known as brain fog. A New York medical college study used a 38-item questionnaire and the
Wood mental fatigue inventory to explore brain fog symptoms. The results of the study showed
that 96% of the POTS patients experience brain fog and most commonly described brain fog as
“forgetful,” “difficulty thinking,” “difficulty focusing,” “cloudy,” and “mental fatigue.” The least
common descriptors were “thought moving too quickly” and “detached.” These descriptors are
indicative of cognitive impairment. Brain fog persists while standing and also reported to
continue when lying down. Recorded brain fog treatments include therapeutic interventions that
fall outside POTS’ standard diagnostic treatment category (Ross et al. 2013).
A major complaint among patients with POTS is gastrointestinal symptoms. GI
symptoms can make it difficult to diagnose a patient and often leads to misdiagnosis. The
substantial problems seen with GI symptoms are significant weight loss, malnutrition, and the
need for invasive treatment to support caloric intake. Decreased oral intake of fluids and
electrolytes especially concerns physicians, because electrolyte and fluid intake are essential to
POTS treatment. The explained GI symptoms are seen in patients with comorbid diseases of the
connective tissue like Ehlers Danlos - hypermobile type and autonomic neuropathy. Delayed
gastric emptying is a significant abnormality seen in these patients. The symptoms likely have
3

Table 1. Clinical Presentation of Symptoms in POTS
Cardiovascular symptoms (pathognomonic)
Cardiovascular
system

Main: Orthostatic intolerance, orthostatic tachycardia, palpitations,
dizziness, lightheadedness, pre-syncope, exercise intolerance
Other frequent symptoms: dyspnoea, chest pain/discomfort,
acrocyanosis, Raynaud’s phenomenon, venous pooling, limb oedema

Noncardiovascular symptoms (accompanying)
General symptoms

General deconditioning, chronic fatigue, exhaustion, heat intolerance,
fever, debility, bedriddenness

Nervous system

Headache/migraine, mental clouding (‘brain fog’), cognitive
impairment, concentration problems, anxiety, tremulousness, light and
sound sensitivity, blurred/tunnel vision, neuropathic pain (regional),
sleeping disorders, involuntary movements

Musculoskeletal
system

Muscle fatigue, weakness, muscle pain

Gastrointestinal
system

Nausea, dysmotility, gastroparesis, constipation, diarrhoea, abdominal
pain, weight loss

Respiratory system

Hyperventilation, bronchial asthma, shortness of breath

Urogenital system

Bladder dysfunction, nycturia, polyuria

Skin

Petechiae, rashes, erythema, telangiectasias, abnormal sudomotor
regulation, diaphoresis, pallor, flushing

Table 1. Summarizes the most common symptoms in clinical presentations of POTS.
Symptoms organized as cardiac or noncardiac and according to the body system.
Note: Reprinted from “Postural orthostatic tachycardia syndrome: clinical presentation,
aetiology and management”, by Fedorowski A., 2019, J Intern Med. 285(4):352–366.
Copyright 2018 by The Association for the Publication of the Journal of Internal Medicine.
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multifactorial causes and thus depend on other comorbid conditions the patient has. Current
thoughts on the causes of these symptoms include GI connective tissue structural abnormalities
and GI tract motility abnormalities, and hormonal secretions by the gut that could directly impair
autonomic transmissions (Mehr et al. 2018). The severe GI symptoms such as impaired gastric
emptying and abdominal pain are more often comorbid with POTS than a sign of POTS and
must be treated separately from POTS. Some patients require more than one diagnosis to treat all
their symptoms properly (Chelimsky 2018).
The onset of POTS can occur from multiple factors. Most commonly, onset occurs after
an immunological stressor on the body like pregnancy, vaccination, viral infection, surgery, and
psychosocial stress. The cause of POTS is not known but current theories include autoimmune
disorder, increased sympathetic activity, catecholamine excess, and sympathetic denervation
(loss of nerve supply) that causes central hypovolemia (decreased blood flow) and reflex
tachycardia (increased heart rate in response to decreased blood pressure) to name a few. Longterm prognosis is not well known, but around 50% of the patient population will spontaneously
recover within 1-3 years (Fedorowski 2019).

POTS Demographic
POTS is estimated to affect 500,000 Americans, with 25% of those being disabled and
unable to work (Grubb 2008), and is considered one of the most common presentations of
orthostatic intolerance globally. Global prevalence studies estimate a range of 0.2 to 1%
prevalence of POTS in developed countries (Zhao 2020). POTS affects younger pre-menopausal
women between the ages of 15-45 years, with around an 80% female predominance (Fedorowski
2019), and other estimates found a female to male ratio of 5:1 (Arnold 2018).
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Subtypes of POTS
The subtypes of POTS are descriptive classification schemes representing heterogeneous
etiologies. Possible explanations for the underlying mechanisms of POTS are outlined in Figure
1 (Arnold 2018, p.6). The multiple pathways involved all conclude in orthostatic tolerance,
POTS’ main symptom (Goodman 2018). Subtypes of POTS include hypovolemic, neuropathic,
hyperadrenergic, volume dysregulation, deconditioning, norepinephrine transporter deficiency,
and mast cell activation.

Figure 1. Multi-pathophysiology of POTS
NE, norepinephrine; NET, norepinephrine transporter; NETi norepinephrine transporter
inhibitor; SNRI, selective norepinephrine reuptake inhibitor; SNS, sympathetic nervous
system.
Note: Reprinted from “Postural tachycardia syndrome – Diagnosis, physiology, and
prognosis”, by Arnold AC, 2018, Autonomic Neuroscience Basic Clin. 215:3–11. Copyright
2018 by Elsevier.
6

Hypovolemia occurs in 70% of POTS patients and is the decrease of plasma volume
(Zhao 2020)(Lei 2019). Secondary hypovolemic states include GI conditions that cause
excessive fluid loss from nausea, vomiting, and diarrhea (Zhao 2020). Figure 2 gives a physical
representation of hypovolemia in the body of a POTS patient. Hypovolemia is triggered from
tachycardia paired with vasodilation in the lower limbs resulting in the cardiac baroreceptors
further increasing tachycardia and resulting in hypovolemia. The hypovolemia then activates
reflex tachycardia in response to the decreased blood pressure and activates vasodilation of
splanchnic arteries that control blood flow to the abdominal and GI organs (Fedorowski 2019,
p.355). The heart is overworking to compensate for the low blood pressure, but the body
responds by vasodilating important blood vessels leading to increased tachycardia.
Studies have shown that the average plasma volume deficit in POTS patients is 13% and
can cause heart rate changes and changes in norepinephrine levels (Lei 2019). Norepinephrine,
along with adrenaline, increases heart rate and blood pumping in the heart, increasing blood
pressure. High norepinephrine levels are indicative of reduced standing renin and aldosterone
levels. Patients have an impaired vasopressor response to angiotensin II. POTS patients have
high angiotensin II levels without increasing angiotensin, giving further support to an abnormal
renin-angiotensin-aldosterone axis. The renin-angiotensin-aldosterone axis involves hormones
that regulate blood pressure and fluid balance (Goodman 2018). Prolonged hypovolemia results
in cardiac atrophy resulting in reduced stroke volumes that further induces tachycardia to
maintain blood pressure and restore blood volume (Arnold 2018). If POTS patients’ reninaldosterone axis worked correctly, then renal sodium and water reabsorption would sufficiently
restore blood volume (Arnold 2018). The degree of hypovolemia varies in patients and involves
treatment that targets the renin-angiotensin system (Zhao 2020).
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Neuropathic POTS is reported in 50% of patients and characterized by sympathetic
denervation in the lower limbs (sympathetic ‘fight or flight’ response of vasoconstriction is
blocked in the lower limbs) with inadequate vasoconstriction upon standing, resulting in venous
pooling (instead of blood vessels in the legs constricting upon standing they relax) (Lei
2019)(Arnold 2018). Patients have decreased norepinephrine spillover in the lower extremities
than normal systemic norepinephrine spillover, leading to the theory that there is norepinephrine
reuptake dysfunction (Zhao 2020). There are currently no criteria to diagnose neuropathic POTS.
Still, a presentation of patchy anhidrosis (inability to sweat normally) in the lower extremities
during a thermoregulatory sweat test is common and can indicate neuropathic POTS (Arnold
2018).
Hyperadrenergic POTS Also presents in 50% of patients (Lei 2019)(Arnold 2018), and
for other surveys, 30 – 60% prevalence was found (Zhao 2020). A characteristic of
hyperadrenergic is norepinephrine levels ≥600pg/mL with a systolic blood pressure of at least
10mmHg within 10 minutes of standing (Lei 2019)(Zhao 2020)(Goodman 2018). Symptoms of
sympathetic activation occur and include palpitation, anxiety, and tremulousness (Lei 2019).
A genetic mutation to the NET gene causes norepinephrine transporter deficiency; the
loss of function gene mutation results in deficient norepinephrine transport (Zhao 2020). An
increase in the supine heart rate can result, putting the body into a hyperadrenergic state with
elevated sympathetic nerve activation (Lei 2019). Certain medications can have negative
consequences in someone with a norepinephrine transporter deficiency. Antidepressant, attention
deficit disorder, and norepinephrine reuptake inhibitor medications must be prescribed sparingly
to patients with POTS because they lead to elevated catecholamine levels leading to tachycardia
(Zhao 2020)(Arnold 2018).
8

Figure 2. Mechanisms of Orthostatic Intolerance and Tachycardia in POTS. Increased
sympathetic activity and circulatory catecholamine excess (2). Autoantibodies acting on
adrenergic and cardiovascular receptors (1). Venous pooling, central low blood pressure,
and peripheral sympathetic denervation (3).
Note: Reprinted from “Postural orthostatic tachycardia syndrome: clinical presentation,
aetiology and management”, by Fedorowski A., 2019, J Intern Med. 285(4):352–366.
Copyright 2018 by The Association for the Publication of the Journal of Internal Medicine.
The relationship between mast cell activation and POTS is still being explored. The
association is poorly understood and presents as sinus tachycardia with severe episodic flushing
(Lei 2019). Mast cells are a type of white blood cell residing close to blood vessels and
peripheral nerves that play roles in the inflammatory response. Mast cells are rich in histamine
and other neuropeptides that, when activated, elicit sympathetic activation in POTS patients
(Arnold 2018) (Fedorowski 2019). Patients have a hyperadrenergic response to a postural change
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resulting in elevated urine methyl and histamines during a flushing episode. The patient will also
commonly have allergic reactions and food sensitivities (Lei 2019). Flushing episodes can be
triggered by multiple stimuli that include standing, exercise, meals, sexual intercourse, and
menstruating with the associated symptoms of lightheadedness, dizziness, shortness of breath,
nausea, and headache (Arnold 2018).
An autoimmune-mediated or inflammatory cause of POTS is also under research.
Autoantibodies have been reported and include M1 to M3 receptors in 87% of POTS patients
(Lei 2019). Positive antinuclear antibodies are present in up to 25% of patients, and a study has
shown an increased proinflammatory level in POTS patients (Zhao 2020). Increased sympathetic
drive and autoimmune markers such as non-specific autoantibodies, G protein-coupled receptors,
and ganglionic ACHR have presented in POTS populations. They are further being studied as
diagnostic indications of POTS (Zhao 2020).
Deconditioning is a result of impaired health-related quality of life and functional
disability. The physical stress seen in those with POTS is comparative to prolonged bed rest and
spaceflight (Arnold 2018). Physical deconditioning and cardiovascular deconditioning are
evident with POTS, and the cause is not clear (Zhao 2020). It is undecided if deconditioning is a
primary cause of POTS or secondary to a chronic illness (Arnold 2018). Gravity dependent roles
may underlie POTS because it has been shown that POTS-like symptoms were induced in
healthy individuals when they were in microgravity environments (Zhao 2020). Short term
exercise programs reduce orthostatic tachycardia and improve systemic hemodynamic blood
volume and left ventricular mass, and improve exercise tolerance in POTS patients (Arnold
2018). Exercise should be considered a promising treatment since a decreased cardiac size and
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ventricular mass decrease of 16% and reduced plasma volume by 20% are commonly seen in
deconditioned patients and could be reversed with exercise (Zhao 2020).

Diagnosis
Steps to diagnose POTS
POTS is a heterogeneous disorder that involves a thoughtful diagnostic approach
considering the individual patients’ circumstances (Goodman 2018). The standard diagnostic
requirements of POTS are a heart rate increase of 30bpm that is sustained or a heart rate that
exceeds 120 bpm that is maintained and occurs within the first 10 minutes of standing and is not
associated with orthostatic hypotension (Grubb 2008)(Lei 2019)(Chung 2020)(Arnold 2018).
Contrary to what’s expected, patients can have a small decline or a modest increase in their
blood pressure when being monitored (Grubb 2008). No other debilitating condition can cause
the above-described criteria for POTS; the criteria needs to be specifically the result of POTS.
Literature states a patient must be symptomatic for 3 (Grubb 2008) to 6 (Chung 2020)(Arnold
2018) months to receive a POTS diagnosis, but others have concern over the long wait period. A
case study by Ha-Yeun Chung describes the case of two females who had a sudden onset and
severe manifestation of POTS with apparent diagnostic symptoms. With a sudden onset of
symptoms, these patients could not wait 3-6 months to receive a diagnosis and proper treatment,
leading Chung to argue that the ≥6-month criteria can lead to misdiagnosis and continued
suffering (2020). A summary of the specific diagnostic criteria for POTS is provided in Table 2.
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Table 2. Diagnostic Criteria for POTS

Table 2. Defines the diagnostic criteria for a diagnosis of Postural Orthostatic Tachycardia
Syndrome (POTS).
Note: Reprinted from “Postural tachycardia syndrome – Diagnosis, physiology, and
prognosis”, by Arnold AC, 2018, Autonomic Neuroscience Basic & Clinical. 215:3–11.
Copyright 2018 by Elsevier.
Upon first meeting with a patient, there is a set method to properly diagnosis said patient.
A detailed history, physical examination, and proper medical testing lead to the diagnosis of
POTS. The first step is to obtain a detailed medical history. The medical history should
document medications, other medical conditions, and a family history (Arnold 2018). Specifics
should be obtained regarding the history of their illness. When did symptoms begin, was the
onset gradual or sudden, were there specific events associated with onset, and what conditions
improve or worsen symptoms are examples of questions to be investigated with a patient (Grubb
2008). A patient’s history determines the symptom burden of tachycardia and what its severity
and triggers are. Specifically, the presence of syncope and impact on daily function and quality
of life should be assessed (Lei 2019). Identifying other comorbid conditions or medications that
could account for the presenting symptoms is essential.
A POTS diagnosis is one of elimination when other factors cannot account for the
symptoms seen. Acute physiological stimuli like panic attacks, pain, exercise, dietary influences
like caffeine and alcohol, medications like anticholinergics and rebound effects of beta-blocker
12

withdrawal and other medical conditions like anemia, dehydration, hyperthyroidism, and
inappropriate sinus tachycardia need to be ruled out as other causes of the tachycardia
experienced by the patient (Arnold 2018). When obtaining a medical history from patients, some
may have already had extensive testing completed and have seen multiple doctors. From a
survey of 700 participants, 27% of patients reported being seen by more than ten physicians
before receiving a proper diagnosis, with a median time of diagnosis being just under six years
(Goodman 2018). Specific comorbid illnesses to be aware of include cardiac disease, joint
hypermobility, chronic fatigue syndrome, bowel irregularities, and autoimmunity or neurological
disorders (Arnold 2018). The majority of patients report onset during early teens to late ’50s and
is standard for symptoms to be reported as modest to start out and then gradually become more
severe. Symptoms can develop acutely, less than a month, subacutely, 1-3 months, and
insidiously, more than three months (Goodman 2018). The most commonly reported
precipitating factors include viral infection, post-concussion, and pregnancy, but most patients
will not have a specific precipitating event (Goodman 2018).
A comprehensive physical examination assesses the biological parameters of the patient.
Laboratory testing is used to rule out other causes of symptoms and includes a complete blood
cell count with hematocrit, thyroid-stimulating hormone levels, electrolyte panel (Lei 2019),
cortisol level, vitamin B12 level, celiac testing, antinuclear antibody testing, and Sjögren
syndrome antibody panel as well as plasma catecholamines when supine and standing. The
extent of laboratory testing should be on a patient by patient basis (Goodman 2018). In all
patients, cardiac testing should be considered and consists of electrocardiography to investigate
cardiac abnormalities (Lei 2019). EEG for intra-arterial blood pressure monitoring and
expanded electrocardiography and transthoracic echocardiograph tests are all necessary to rule
13

out other conditions. These tests can have normal results in a patient with POTS but will rule out
pathologies like orthostatic syncope, heart rhythm disorders, arrhythmia, and drug side effects
(Chung 2020). A thorough examination of heart rate and blood pressure should be performed on
the patient while supine, sitting, and immediately upon standing (Grubb 2008).
Tilt table testing is a gold standard for diagnosing POTS. Typical results of a POTS
patient compared to a healthy patient during a head-up tilt test is shown in figure 3 (Arnold 2018,
p.5). Figure 3 demonstrates how an excessively high heart rate in POTS patients doesn’t increase
blood pressure like expected but will maintain blood pressure, showing the blood volume
system’s dysregulation. The two types include standing tilt table test and head-up tilt test.
Upright (head up) tilt table testing identifies vasovagal syncope but can result in false positives.
Healthy patients will experience induced syncope, and thus POTS patients’ results cannot be
considered conclusive (Stewart 2019). The difference in Physiology between active and passive
standing is not accounted for in the current POTS diagnostic criteria according to a study
performed by Walker Plash and associates that specifically tests whether a passive head-up tilt
table test would produce a more significant increase in heart rate then an active stand test would.
The researchers agree that physicians need to differentiate between testing patients with a tilt test
and a stand test; 15% of healthy subjects experienced vasovagal episodes with the passive tilt test
representing 15% false positives. They concluded that an active stand test is more specific than a
passive tilt test (Plash2013).
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Figure 3. Head-Up Tilt Table Testing: Hemodynamic Pattern in healthy control and POTS
patients.
(A) Modest heart rate increase with no change in blood pressure seen in a healthy individual.
(B) Excessive rise in heart rate with a stable blood pressure seen in patient with POTS.
Note: Reprinted from “Postural tachycardia syndrome – Diagnosis, physiology, and
prognosis”, by Arnold AC, 2018, Autonomic Neuroscience Basic Clin. 215:3–11. Copyright
2018 by Elsevier.
Formal autonomic testing analyzes neurovascular responsiveness to assess hypovolemia
(Lei 2019). Exercise testing can be used in patients that complain of exercise intolerance to
quantify exercise capacity (Lei 2019). During a physical examination, extremities can appear
blueish with discoloration that suggests peripheral vascular pooling (Grubb 2008). Other tests
specific to the autonomic nervous system include thermoregulatory sweat testing and
15

sympathetic skin potential serum samples (Grubb 2008). MRI of the head and cervical spine can
view cerebral spinal fluid and see if any obvious abnormalities are present. The duplex
ultrasound of arteries that supply the brain is a useful diagnostic test to find syncopal collapse
evidence (Chung 2020). A neurological and psychiatric evaluation can be completed to rule out
psychosomatic etiology (Chung 2020). These evaluations are especially important since Brent
Goodman’s study found 83% of respondents being given a psychiatric diagnosis before being
diagnosed with POTS (2018). A group of researchers from the European Society of Cardiology
studied the relationship between cerebral tissue oxygenation saturation and heart rate. It was
found that POTS patients have lower cerebral tissue oxygen saturation during head up tilt
compared to patients with normal responses to the head up tilt and that the heart rate increase
was associated with a decrease of cerebral tissue oxygenation and this association was not seen
in the controls. Previous studies measured cerebral blood flow and found that it was inconsistent,
showing that both higher and lower levels of cerebral blood flow in POTS patients was seen.
These results led the researchers to conclude that there is an unknown variable still left as to the
mechanism of POTS (Kharraziha 2019).
There is not a single test to exclusively diagnosis POTS. Much of diagnosing POTS
focuses on excluding conditions that mimic or exasperate POTS and identify comorbid
conditions that impact management (Goodman 2018). Recommendations from the Heart Rhythm
Society are summarized in table 3 and include steps that should be taken when seeing a patient
who is possibly presenting with POTS (Arnold 2018, p. 5). Evaluation of possible POTS
involves a careful history, thorough clinical examination, and thoughtful diagnostic evaluation.
POTS is a convergence of multiple pathophysiological processes, and therefore the precise
etiology remains unknown. Several subtypes of POTS are described that have overlapping
16

clinical features without clearly accepted definitions and thus are not currently helpful as
individual patient labels. Patients must be treated on a patient by patient basis, based on their
symptoms and the context they present within.

Table 3. Heart rhythm society recommendations for evaluation of POTS
Investigation

Utility

Comment
Initial Evaluation

Medical history

Essential

Document medications, other medical conditions, diet and
exercise history, family history, and details on nature of
tachycardia including chronicity, triggers, modifying factors,
presyncopal or syncopal episodes, symptoms and impact on daily
activities.

Physical
examination

Essential

Detailed cardiovascular, neurologic, autonomic, and other systems
assessment.

Orthostatic vitals

Essential

Blood pressure and heart rate should be measured while lying
down (>5 min) and ideally again after 1, 3, 5, and 10 min of
standing.

Electrocardiogram

Essential

Rule out pre-existing cardiovascular disease and cardiovascular
conduction abnormalities.
Additional Evaluation

Blood work

Some
patients

In patients with evidence for specific underlying causes such as
dehydration, anemia, and hyperthyroidism. Supine and standing
norepinephrine levels in patients with evidence for
hyperadrenergic POTS.

Cardiovascular
testing

Some
patients

In patients with suspected cardiac conduction or structural
abnormalities (e.g. Holter monitor, echocardiogram, exercise
stress testing).

Head-up tilt table
testing

Some
patients

In patients with normal orthostatic vital signs with high clinical
suspicion, or in patients with convulsions or seizure disorder.

Autonomic
function tests

Some
patients

In patients with symptoms of autonomic neuropathy, or in patients
whose symptoms do not resolve or markedly improve with
treatment.

Table 3. The Heart Rhythm Society recommendations for evaluating POTS in patients,
explaining when certain diagnostic tests are helpful for a correct diagnosis.
Note: Reprinted from “Postural tachycardia syndrome – Diagnosis, physiology, and
prognosis”, by Arnold AC, 2018, Autonomic Neuroscience Basic & Clinical. 215:3–11.
Copyright 2018 by Elsevier.
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Misdiagnoses
A survey of 4835 participants explored the diagnostic journey of patients living with
POTS. The study used an online community-based cross-sectional survey with POTS patients
diagnosed by a physician. The survey included predominantly white (93%) and female (94%)
POTS patients of childbearing age, with half of the participants having developed symptoms
around the age of 14. Clinicians assessed around 9% of respondents at expert sites in autonomic
disorders. Table 4 (Shaw 2019, p.442) summarizes the essential information provided by
participants about their diagnostic journey. Frequently reported were patients being
misdiagnosed with other ailments, seeing many physicians prior to diagnosis with POTS, and
suggesting POTS as a potential diagnosis to their physician. Respondents reported on average
that they saw 7±11 physicians before a diagnosis, and 21% reported having to see more than ten
doctors before a diagnosis was made. On average, patients waited a median time of 24 months
after the presentation of initial symptoms before a POTS diagnosis was made (Shaw 2019).
In the same study, patients who waited more than ten years after initially visiting a
physician for symptoms made up 15% of the respondents. Interestingly female participants
reported longer diagnostic delays of 5 ±7.2 years than their male counterparts, waiting 3 ±4.4
years even though the illness is more prevalent in females. There was no difference in diagnostic
delays seen between races. Improvement has been seen in diagnostic delays with 11.6-month
shorter wait times for patients diagnosed after 2009 compared to those diagnosed from 2000 –
2009. Despite the improvement in diagnostic delay, since 2009, there is still 4.7±6.9 years of
delay time. Of the correspondents, 75% of patients reported that a physician misdiagnosed their
POTS symptoms before being diagnosed with POTS, as is seen in Table 4, and prior to
diagnosis, 67% of patients saw a physician who acknowledged a physical illness but was unsure
18

how to proceed. Of participants, 77% encountered a physician who suggested their symptoms
were due to a psychiatric or psychological problem before receiving a POTS diagnosis.
Furthermore, 28% of patients report that they were suffering from psychological issues before
they were diagnosed with POTS. Of the patients diagnosed with POTS, 37% of participants
reported being told that they were suffering from a psychiatric problem. Misdiagnosis is likely to
occur in POTS because of the many possible and common comorbid diseases seen with POTS
that include asthma, autoimmune diseases, iron deficiency anemia, and gastroparesis, with
prevalence rates higher in the POTS population than the general public (Shaw 2019).
Table 4. Diagnostic Journey in POTS
Patients

Table 4. Diagnostic Journey in POTS
Note: Reprinted from “The face of postural tachycardia syndrome – insights from a large
cross‐sectional online community‐based survey”, by Shaw BH, 2019, Journal of Internal
Medicine. 286(4):438–448. Copyright 2019 by the authors.
19

Julian Stewart and associates conducted a study to evaluate false positives with tilt table
testing. Upright tilt table tests were found to result in false positives because of tilt induced
fainting. It was found that POTS like fainting is induced in healthy volunteers because
splanchnic blood volume was markedly decreased, causing splanchnic pulling in the legs. The
head-up tilt table was inducing fainting in normal patients and cannot be used to diagnose POTS
patients reliably (Stewart 2019).
Andrew Owens and associates investigated the hypothesis that POTS patients experience
atypical anxiety phenotypes with affective symptoms related to apprehension and vigilance of
physiological feedback rather than neurotic or trauma-related factors. They found that patients
with POTS were more sensitive to anxiety than the controls regarding the anxiety sensitivity
index; specifically, all patient groups scored higher on the item “it scares me when I feel faint”
than controls. POTS patients scored higher than controls on the global body vigilance scale.
There was no difference between controls and POTS patients regarding the childhood traumatic
events scale. There were no significant differences in the self-consciousness scale revised. This
study provides important insight when diagnosing a patient with POTS and gives variables to
compare what is normal in a POTS patient and what is not, allowing proper diagnosis of
psychosomatic disorders (Owens 2017).

Quality of Life After Diagnosis
A study conducted by Elizabeth Keating and associates focused on physical functioning
and disability in children and adolescents with chronic pain. The study included 141 pediatric
patients from the ages of 7 to 20 years, with all patients experiencing chronic pain and clinical
symptoms that suggest POTS. Respondents completed the FDI’s functional disability inventory,
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a 15-item questionnaire that measures physical functioning and disability in children and
adolescents with chronic pain. No difference was found between pain patients with and without
POTS in regard to depression or functional disability. There was a significant difference between
the groups for anxiety, with POTS patients reporting more anxiety. The symptoms reported by
the POTS patients include suffering from fatigue 94%, with dizziness 69%, nausea and vomiting
69%, memory and concentration problems 61%, and with fainting 23%. The most common
chronic pain locations were abdominals pain 49%, headaches 49%, joint/extremity pain 43%,
back/neck pain 38%, and chest pain 19%. From the study, adolescents with chronic pain and
adolescents with chronic pain and POTS experience the same moderate functional disability and
score similarly (Keating 2017).
A postal survey conducted on POTS patients from a hospital in Southwest England
assessed patient demographics, diagnosis times, diagnosis methods, treatments, and treatment
response. They found that having POTS causes life quality to decline by around 4 pts from 7.5 to
3.75 on a 10-point scale. Around ½ of the respondents reported improved day-to-day functioning
from 3.21 to 6.14 after receiving treatment. A delay in receiving a diagnosis was reportedly as
common as seeing multiple healthcare professionals before receiving adequate treatment. Acute
physicians and cardiologists diagnosed the majority of patients. Every patient diagnosed with
POTS was also continuously experiencing dizziness and fatigue. A majority of patients were
experiencing brain fog, palpitations, nausea, temperature disturbance, tremor, chest pain, bladder
disturbance, visual changes, and sleep disturbances. Around 45% of patients had injured
themselves directly because of POTS. After diagnosis and effective treatment, symptomatic
relief is had in POTS patients, and quality of life improvements are possible (Flack 2018).
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A study examined self-reported autonomic symptoms in POTS patients and used the
COMPASS-31 to compare POTS patients’ scores, compare autonomic function/neuropathy
(AF/N), and compare healthy controls. Patients with POTS diagnosis reported more significant
symptom burden across all functional domains of autonomic function with findings consistent
with clinical experience and prior reports by POTS patients. The study used regression analysis
to exclude the possible influence of age, gender, and effective scores on the gathered data. The
article concluded that POTS patients have significantly higher autonomic symptom burden than
healthy controls with scores spanning multiple autonomic function domains. It was also
confirmed that the severity of POTS’ overall symptom burden is similar to AF/N autonomic
failure/neuropathy (Rea 2017). POTS quality of life can be compared to other patients of AF/N.
Lastly, a study on the quality of life after diagnosis with 1702 patient reports found that
patient symptoms had generally improved a little, 42% of patients. While 29% said their
symptoms had improved a lot, and 10% of patients reported no change in symptoms, with 44%
of patients claiming their symptoms had worsened, and 63% of respondents believed they have
always had a tendency to have POTS-like symptoms for most of their lives. And of the
participants who said that their symptoms improved, 29% reported medications as the
predominant reason for this improvement. The survey saw that 83% of respondents also suffered
from at least one additional medical condition (Shaw 2019).
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Treatment
Pharmaceutical Medication
Drug therapy should be used when nonpharmacological interventions do not adequately
relieve symptoms. Treatment needs to be tailored to the patient because of the heterogeneity of
POTS. No medications are currently approved by the US Food and Drug Administration or
Health Canada, specifically for treating POTS. Several drugs can expand blood volume and lead
to a reduced orthostatic tachycardia response. Erythropoietin addresses the deficit in red blood
cell volume in POTS patients. The medication causes vasoconstrictor effects and improves red
blood cell volume in patients without exceeding plasma volume, ultimately reducing orthostatic
tachycardia. Drawbacks include a high cost, subcutaneous administration, and risk of lifethreatening complications such as myocardial infarction and stroke.
Desmopressin is a synthetic version of a natural antidiuretic hormone that increases
kidney mediated free water reabsorption without sodium retention. The water reabsorption
reduces the upright heart rate in patients with POTS and improves symptom burden. Adverse
effects include edema, headache, and hyponatremia and are a concern with daily use. Patients are
advised to use desmopressin no more than once a week for acute improvement in symptoms, and
intermittent monitoring of serum sodium levels is recommended for safety. Fludrocortisone is a
synthetic aldosterone analog that enhances sodium and water retention. There is currently no
high-level evidence that this medication is effective for POTS and possible adverse effects
include hyperkalemia, hypertension, fatigue, nausea, headache, and edema (Lei 2019).
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A systematic review and meta-analysis that included eight studies assessing beta-blockers
efficacy and treating POTS in children and adolescents found that beta-blockers had significantly
higher efficacy than their comparable controlled treatments. Beta-blockers might also be more
effective than controlled treatments. During a standing test, the beta-blocker group lowered the
heart rate increment and significantly decreased in symptom scores than the controlled
treatments. Overall, it was concluded that beta-blockers are effective in treating POTS in
adolescents and alleviate orthostatic intolerance, improving hemodynamic abnormalities.
Metoprolol, a beta-blocker, had efficacy in 79.5% of POTS patients in this study, and the control
group had 57.3% efficacy. Beta-blocker efficacy comes from blocking cardiac β-1 receptors and
provides a negative inotropic effect, slowing the heart and decreasing tachycardia. Another
hypothesis is that beta blockers inhibit renin secretion by inhibiting β-1 receptors of the
juxtaglomerular cells. Inconsistencies in the efficacy of beta-blockers are found throughout
multiple studies, and reasons for these contradictions seem to be multifaceted. POTS is a
heterogeneous disorder, and one drug is unlikely to treat all manifestations (Deng 2019).

Lifestyle Changes
POTS’ nonpharmacological treatment involves physical reconditioning through exercise
training and volume expansion from increased salt and fluid intake. Cardiovascular
deconditioning is a common feature in POTS patients regardless of the etiology. Heart size and
mass can be smaller in patients with POTS, even when compared to age and sex-matched healthy
individuals. Plasma and blood volume reduction are seen in those with POTS. A barrier to
treatment is that most individuals have significant limitations for low-intensity physical activity.
A small heart coupled with low blood volume causes a fall in stroke volume during standing with
the heart rate increasing to compensate, known as the baroreflex. Studies done on astronauts in
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zero gravity environments that induce bed rest deconditioning to study how to counteract
deconditioning can be used to brainstorm POTS treatments. Patients will often experience
periods of bed rest during their illness. Studies show that exercise training combined with
replenishing plasma and blood volume increases cardiac size and mass, preventing
cardiovascular deconditioning. To increase blood volume exercise training and increased salt and
fluid intake is a necessary part of POTS treatment. Fu put together an effective treatment plan
that involves 4 categories of nonpharmacological treatments geared towards reversing body
deconditioning and improving blood volume. These treatments are considered cost-effective,
simple, and provide low side effects (Fu 2018).
Regular exercise is a pillar of POTS treatment and is especially needed when an illness
presents in a chronic and debilitating fashion. A workout regimen should contain aerobic
endurance reconditioning with partial strength resistance training focused on the lower body.
Supervised training is mo preferred. Current exercise training programs for POTS are based on
spaceflight / head-down bedrest exercise countermeasures. How to train muscles in zero gravity
are focused on exercising that promote proper blood flow. Exercise training increases peak
oxygen uptake by 8% and cardiac size and mass by 12% and 8%, and blood volume by 6%.
Contrary to pharmacological therapies (β-blockers), exercise training improved patient
well-being and quality of life. Research has shown 53% of patients in studies, and 71% in the
POTS registry improved with exercise therapy and ‘no longer meet the objective criteria for
POTS’ and are in remission. Factors that would limit an exercise program for a POTS patient
include medical problems, personal reasons, and training being ‘too difficult’ (Fu 2108).
Endurance training for POTS patients should begin with a horizontal mode of training. A
specific recommendation is to row; rowers have the largest hearts of all competitive athletes.
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Spread all workouts throughout the week to abstain from taking multiple days of no exercising.
As a patient continually exercises, they will gradually increase heart mass and continuously
become more fit. Each increase in ability should be met with an increase in training difficulty;
this builds endurance overtime (Fu 2018).
Resistance training focuses on the lower body and core to strengthen the muscles that act
as a pump in an effort to increases venous return. Weightlifting is recommended and can start
from once a week to twice a week and so on and so forth. It is recommended that workouts are
performed on seated equipment until the patient is appropriately strong and fit. Other options are
to use a floor mat, resistance bands, or physio-ball similar to Pilates. Weight training causes
muscle soreness for days after exercise and can be done after cardio workouts but not too often,
ensuring there are days between resistance workouts (Fu 2018).
Volume expansion of plasma and blood is necessary for POTS patients who have reduced
plasma and blood volumes. Low volume causes small stroke volume and activates reflex
tachycardia while standing. Patients need chronic volume expansion through salt and fluid intake
and/or sleeping in a head-up position. Both therapies increase plasma volume and support
exercise training. Salt loading of up to 10g/day increases plasma volume and orthostatic
tolerance. Salt can be consumed progressively and slowly increased every day by adding salt to
foods. Salt tablets are not recommended and cause osmotic loading in the stomach, resulting in
nausea, vomiting, dehydration, and further blood/plasma volume reduction. Water uptake should
increase with salt uptake. 3L per day is a starting recommendation. High salt and water regimen
should be started when exercise training is started. Another method for volume expansion is
sleeping in the head-up position. Sleeping is done with the head, or the body elevated during
sleep either by extra pillows or hard objects under the front bedposts. Sleeping in this position
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allows the body to retrain itself gradually. Mild orthostatic stress promotes blood volume to
move to the lower extremities causing a decreased central blood volume and activating the
angiotensin-aldosterone system resulting in saltwater retention and volume expansion. Head-up
tilt at night causes chronic volume expansion in patients with autonomic failure. The magnitude
of volume expansion using head-up tilt is unknown and needs to be further investigated (Fu
2018).
Physical countermeasures require little or no equipment and involve using your body to
combat orthostatic tolerance. Table 5 (Fu 2018, p.24) summarizes physical maneuvers to counter
orthostatic tolerance. Squeezing a rubber ball increases mean arterial pressure. The muscle
contraction promotes sympathetic activation or vagal withdrawal, commonly known as the
exercise pressor reflex. To increase arterial pressure, patients can contract their abdominal and
leg muscles while squeezing a rubber ball. These measures are best used to counter or delay
neutrally mediated syncope. It will not provide long-term relief but acts as a quick fix when
needed (Fu 2018).
Similar to ball squeezing is leg crossing and muscle tensing. The Dutch leg-crossing
maneuver done by crossing one foot in front of the other and squeezing the thigh and gluteal
muscle together will restore venous return and prevent further blood pooling in the lower body
and increases cardiac output as well as mean arterial pressure while upright. With the increase in
intramuscular pressure, the vein’s transmural pressure decreases such that venous distension is
reduced, and cardiac output increases shifting blood centrally. Muscle pumping of the legs
translocates blood against a substantial gradient. Squatting is effective because it involves
bending, muscle tensing, and sitting. For a brief increase in circulation, forceful coughing can be
effective. The forceful cough raises intrathoracic pressure forcing blood into the aorta and its
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branches, and during inspiration, blood is drawn into the right heart, completing an established
circulation. Cough cardiopulmonary resuscitation can prevent loss of consciousness when time is
needed before conventional cardiopulmonary measures can be taken (Fu 2018).

Table 5. Physical maneuvers to counter orthostatic tolerance
Maneuvers

Brief description

Action mechanisms

Squeezing a rubber
ball

Static or rhythmic muscle contraction to
increase mean arterial pressure and
prevent orthostatic intolerance or syncope

Sympathetic activation, vagal
withdraw, or both via the
exercise pressor reflex

Leg crossing and
muscle tensing

Crossing one foot in front of the other and
squeezing the thighs and gluteal muscles
together

Restoration of venous return
and prevention of further blood
pooling in the lower body

Muscle pumping

Swaying, shifting, tiptoeing, or walking

Activation of the muscle pump
in the legs to increase venous
return

Squatting, sitting,
lying down

Squatting is a combination of sitting,
bending and muscle tensing; sitting and
lying down to reduce/eliminate
gravitational stress

Facilitating venous return from
the legs to the heart and
increasing central blood volume

Cough
cardiopulmonary
resuscitation

Forceful coughing

Increasing intrathoracic
pressure to force blood out of
the chest into the aorta and its
braches

Negative-pressure
breathing maneuver

Breathe through an inspiratory impedance
threshold device

Using endogenous respiratory
pump to increase venous return
and central blood volume

Skin surface cooling

Spray cold water, use fan and cooling
towel to cool the skin in a hot
environment

Decreasing blood supply to the
skin and reducing clinical
symptoms

Table 5. Physical maneuvers to counter orthostatic tolerance
Easy, low-equipment maneuvers that act as physical countermeasures to combat orthostatic
tolerance symptoms and increased cardiac output.
Note: Reprinted from “Exercise and non-pharmacological treatment of POTS”, by Fu Q,
2018, Autonomic Neuroscience Basic and Clinical. 215:20–27. Copyright 2018 by Elsevier.
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A multitherapeutic/multidisciplinary approach has been used to aid patients. It can include
physical therapy, biofeedback, occupational therapy, recreational therapy, relaxation training,
stress management, wellness instruction, and pain/physical symptom management training (Fu
2018).

Apparel
Compression stockings are effective at reducing peripheral venous pooling and enhance
venous return to the heart. Waist-high stockings with compression of 30-40 mm HG deliver the
best results (Lei 2019). By regulating fluid distribution in the lower extremities, orthostatic
symptoms can be prevented. Compression stockings are effective at treating lower extremity
edema by distributing blood and extravascular fluid with the help of external forces. Stockings
aren’t often adhered to as a treatment because stockings are reported to be uncomfortable.
Particularly difficult is putting on and taking off the waist-high stockings. A new type of
compression stocking is being designed by the University of Minnesota College and Design
Wearable Technology Lab that can switch compression on and off, allowing removal with
minimal friction. With their design, the degree of compression can be altered based on comfort
level. It was found that Change in heart rate was significantly lower when garments of
compression were worn during the tilt table test. They concluded that the compression garments
cause a decrease in venous pulling, which allowed an increase in venous return to the heart,
causing a higher stroke volume and ultimately reducing heart rate. Also found was that the fit of
a compression garment is important in correctly producing the intended cardiovascular changes.
The garments can ultimately serve to improve venous return to the heart and is designed as an
active compression garment. These active garments have similar results to compression
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stockings and are a new novel treatment alternative. The athletic garments allow patients to
adhere to their compression regimen and improve patient quality-of-life (Kelly 2019).
Gradient compression stockings decrease venous pooling, increase systolic blood
pressure, reduce stroke volume and cardiac output, and prevent tachycardia upon standing. Leg
and abdominal compression are more effective than solo leg compression. Abdomen-high
compression stockings are the recommendations. NASA garments consist of three pieces of twolegs talking and a biker-style short, less intimidating than the commercially offered one-piece
stocking. Also included in the astronaut attire are zippers at the ankles and on the shorts to lessen
compression during necessary times. This feature would be helpful in commercial compression
garments (Fu 2018). A summary of nonpharmacological treatments for POTS is summarized in
figure 4 (Fu 2018 p.23). Each therapy is useful for a different pathway within POTS. When
combined, it creates an effective treatment plan to return a patient to functioning levels with a
higher quality of life.
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Figure 4. Nonpharmacological treatments of POTS
Each treatment is aimed towards a different physiological process found within POTS. (a)
Exercise trainingdecreases cardiac atrophy. (b) Salt-fluid intake and upright sleeping
deaacrease hypovolemia. (c) Compression garments mechanically reduce venous pooling in
legs. (d) Physical countermeasures relieve the symptoms of POTS from reflex tachycardia.
Note: Reprinted from “Exercise and non-pharmacological treatment of POTS”, by Fu Q,
2018, Auton Neurosci Basic Clin. 215:20–27. Copyright 2018 by Elsevier
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Summary
Postural Orthostatic Tachycardia syndrome affects a large majority of the younger female
population. POTS presents as a heart rate increase of 30bpm that is sustained or a heart rate that
exceeds 120 bpm that is maintained and occurs within the first 10 minutes of standing and is not
associated with orthostatic hypotension. The symptoms that occur from the body’s dysregulation
ranges from pre-syncope, palpitations, and heat intolerance to abdominal pain, polyuria, and
nausea. POTS affects females more than males and is more prevalent in Caucasian females. The
multiple subtypes of POTS make diagnosis sometimes trickier but ultimately leads to a wellrounded treatment plan for the individual. Diagnosing POTS takes a healthcare provider that
addresses the multiple steps in diagnosing a patient with POTS. Collecting a detailed history and
running the correct diagnostic tests. Misdiagnosis is more common in POTS because
comorbidities are in a large percentage of the POTS population. Quality of life generally
increases after receiving a diagnosis and subsequent treatments. Nonpharmacological treatments
are preferred because they are proven to be as effective as pharmaceutical medications.
Treatment focuses on reducing orthostatic tolerance and increasing plasma blood volume.
Changing sleeping habits and learning easy equipment-free techniques fulfills a comprehensive
treatment program. Regular exercise helps condition the body into correct responses to
tachycardia, and increasing salt and water allows the body to build up its blood volume. Lastly,
compression stockings are effective co-treatment to support the body throughout the day by
supporting blood flow and prevent venous pooling. POTS is debilitating but can be successfully
treated with a proper diagnosis and treatment plan.
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